195 related articles for article (PubMed ID: 14974331)
1. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
[No Abstract] [Full Text] [Related]
2. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
[No Abstract] [Full Text] [Related]
3. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
[No Abstract] [Full Text] [Related]
4. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Cohn JN
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
[TBL] [Abstract][Full Text] [Related]
5. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
[TBL] [Abstract][Full Text] [Related]
6. [The ONTARGET trial].
Verdecchia P; Terrosu P
G Ital Cardiol (Rome); 2009 Feb; 10(2):67-72. PubMed ID: 19348142
[No Abstract] [Full Text] [Related]
7. [What is better here: ACE inhibitor or AT1 blocker?].
MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
[No Abstract] [Full Text] [Related]
8. Study at up to 700 sites will build on landmark HOPE trial.
Cardiovasc J S Afr; 2001; 12(2):127-30. PubMed ID: 11474703
[No Abstract] [Full Text] [Related]
9. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
[No Abstract] [Full Text] [Related]
11. [Therapy of hypertension. Lasting organ protection moves into the foreground].
MMW Fortschr Med; 2003 Nov; 145(47):62. PubMed ID: 14738040
[No Abstract] [Full Text] [Related]
12. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
13. [Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].
MMW Fortschr Med; 2003 Jun; 145(23):59. PubMed ID: 12854231
[No Abstract] [Full Text] [Related]
14. [Further options with ramipril. Besides cardio- and nephro-protection diabetes prevention, too?].
MMW Fortschr Med; 2003 Sep; 145(39):47. PubMed ID: 14649075
[No Abstract] [Full Text] [Related]
15. [Ramipril after myocardial infarct. Long lasting cardiovascular protective action].
MMW Fortschr Med; 2003 Sep; 145(39):46. PubMed ID: 14649074
[No Abstract] [Full Text] [Related]
16. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
17. The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
Lamy A; Wang X; Gao P; Tong W; Gafni A; Dans A; Avezum A; Ferreira R; Young J; Yusuf S; Teo K;
J Med Econ; 2011; 14(6):792-7. PubMed ID: 21981559
[TBL] [Abstract][Full Text] [Related]
18. [ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].
Einecke D
MMW Fortschr Med; 2008 Sep; 150(38):14, 16. PubMed ID: 18983047
[No Abstract] [Full Text] [Related]
19. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Böhm M; Baumhäkel M; Mahfoud F; Werner C
Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Sharma A; Baliga V;
J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
